Koning Corporation
PrivateLast Round
Series C
May 22, 2025
Est. Valuation
$41.67M
Total Funding Raised
$9.41M
Company Overview
Koning Corporation operates in Healthcare & Life Sciences and is based in Norcross, Georgia. Its latest recorded funding round was a Crowdfunding round in January 2022.
Koning Corporation is a health technology company that develops and commercializes the Koning Breast CT (KBCT), a compression-free, 3D breast imaging device for earlier cancer detection.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical Devices, Medical AI
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Usage-Based SaaS, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Koning Corporation Comparables
Compare Koning Corporation with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Izotropic Corporation | 86% | |
| GratXray AG | 81% | |
| Seno Medical | 80% |
For institutional investors. Book with your work email.
Koning Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 22, 2025 | ||||
| Crowdfunding | Jan 17, 2022 | ||||
| VC Round | Nov 25, 2014 | ||||
| Grant | Sep 12, 2011 | ||||
| Grant | May 11, 2005 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Koning Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Excell Partners | Grant |
| National Institutes of Health (NIH) | Grant |
| Republic Europe | Crowdfunding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 31, 2026
Monthly visitors increased 36% MoM to 11.5K.
- Nov 10, 2025
Monthly visitors grew 110% MoM, reaching 8.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_inOct 1, 2026
In Oct '26, Koning Health expands its United States presence through a HealthTrust agreement that makes it an approved vendor and gives member healthcare organizations a streamlined path to access Koning Vera Breast CT.
For institutional investors. Book with your work email.
Koning Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Koning Corporation's valuation, stock price, and market status.
Is Koning Corporation a public or private company?
Koning Corporation is a private company.
What is the current stock price of Koning Corporation?
Koning Corporation is a private company, so its shares have no public market price. Caplight tracks Koning Corporation's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Koning Corporation worth (valuation)?
Koning Corporation's valuation is estimated at $41.7M based on funding round data.
Can I buy Koning Corporation stock?
Koning Corporation shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Koning Corporation's last funding round?
Koning Corporation's most recent funding round was Series C on May 22, 2025.
Who are the main investors in Koning Corporation?
Key investors in Koning Corporation include Excell Partners, National Institutes of Health (NIH), Republic Europe.
Will Koning Corporation IPO soon?
No public IPO plans have been announced for Koning Corporation.
How can I track Koning Corporation secondary market activity?
Caplight tracks bids, offers, and trades in Koning Corporation's shares on secondary markets.